Context During the past 2 decades, a major transition in the clinical characterization of
psychotic disorders has occurred. The construct of a clinical high-risk (HR) state for …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

The “at risk mental state” for psychosis approach has been a catalytic, highly productive
research paradigm over the last 25 years. In this paper we review that paradigm and …

The brain sciences are influencing our understanding of human behavior as never before,
from neuropsychiatry and neuroeconomics to neurotheology and neuroaesthetics. Many …

In order to bring about implementation of routine screening for psychosis risk, a brief version
of the Prodromal Questionnaire (PQ; Loewy et al., 2005) was developed and tested in a …

These guidelines from the British Association for Psychopharmacology address the scope
and targets of pharmacological treatment for schizophrenia. A consensus meeting, involving …

Introduction: Prevention of psychosis has become a major objective of modern clinical
psychiatry. An increasing number of new services have been established in Europe and in …

Background Clinical research into the Clinical High Risk state for Psychosis (CHR‐P) has
allowed primary indicated prevention in psychiatry to improve outcomes of psychotic …

BackgroundThere is concern that delaying treatment for psychosis may have a negative
impact on its long-term course. A number of countries have developed early intervention …

Background The benefits of indicated primary prevention among individuals at Clinical High
Risk for Psychosis (CHR-P) are limited by the difficulty in detecting these individuals. To …